Prasad, G RDalal, A VTongaonkar, H BChatterjee, SKamat, M R1995-10-012009-06-021995-10-012009-06-021995-10-01Prasad GR, Dalal AV, Tongaonkar HB, Chatterjee S, Kamat MR. The impact of cisplat based chemotherapy on advanced ovarian cancer. Journal of Postgraduate Medicine. 1995 Oct-Dec; 41(4): 95-8http://imsear.searo.who.int/handle/123456789/117060Cisplatinum based chemotherapy has become the standard treatment for ovarian cancers due to its proved superiority over non-cisplat based regimes. However, the therapeutic impact of cisplat based regimes compared to cheaper non-cisplatinum based regimes is questionable when multiple variables such as residual disease, histologic type, grade are introduced. This report is a study of 110 Stage III ovarian cancer patients from 1985-89, with cisplat (n = 69) and non cisplat (n = 41) based chemotherapy. The results of both regimes with reference to the multiple variable factors are presented. We conclude that cisplat based regimes appear to be superior to non-cisplat based regimes except probably in poorly differentiated ovarian tumors where the results were similar with either regimen.engAntineoplastic Combined Chemotherapy Protocols --administration & dosageCisplatin --administration & dosageCyclophosphamide --administration & dosageDoxorubicin --administration & dosageFemaleFluorouracil --administration & dosageHumansMethotrexate --administration & dosageOvarian Neoplasms --drug therapySurvival RateTreatment OutcomeComparative Study